Hikma bio-thera
WebDec 1, 2024 · Amman, December 1, 2024 - Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced an exclusive licensing and distribution agreement with Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer. WebAug 27, 2024 · The agreement also provides Hikma with a first-right-to-negotiate to add Europe (excluding CIS countries)," Hikma explained. The company will pay Bio-Thera USD20 million upfront and up to USD130 ...
Hikma bio-thera
Did you know?
WebNov 4, 2024 · Chinese biosimilars specialist Bio-Thera Solutions has struck a licensing deal with Intract Pharma that will give it access to drug delivery technologies that will be used … WebAug 27, 2024 · Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody that is a proposed biosimilar referencing Stelara ® (ustekinumab), in the United States (US).
WebApr 19, 2024 · Bio-Thera and Hikma have partnered to commercialize BAT2206, wherein Hikma would have the commercialization rights for the United States and negotiation … WebAug 30, 2024 · Bio-Thera Solutions Bert E. Thomas IV +1 410 627 1734 (mobile) Senior Vice President, Business Development [email protected] Hikma Pharmaceuticals PLC Susan Ringdal +44 (0)20 7399 2760/ +44 7776 477050 EVP, Strategic Planning and Global Affairs [email protected] Steve Weiss +1 732 720 2830/ +1 732 788 8279 …
WebBio-Thera is eligible for an upfront payment of $20 million as well as further development and commercial milestones of up to $130 million. "Partnering with Hikma to commercialize BAT2206, our ustekinumab biosimilar, further validates the high quality of the work performed at Bio-Thera," said Dr. Shengfeng Li, CEO of Bio-Thera Solutions. WebAug 27, 2024 · (RTTNews) - Bio-Thera Solutions, Ltd. has entered into a commercialization and license agreement with Hikma Pharmaceuticals PLC (HIK.L) to commercialize BAT2206, the company's ustekinumab...
WebNov 4, 2024 · London, 4 November 2024 – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Siggi Olafsson, Hikma’s CEO, said: “Our business continues to perform strongly, enabling us to reiterate our full year guidance to achieve another year of growth.
WebOn August 27, 2024 Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) reported that they have entered into a commercialization and license … baurag berlinWebAug 27, 2024 · Bio-Thera is eligible for an upfront payment of $20 million as well as further development and commercial milestones of up to $130 million. “Partnering with Hikma to … Hikma will not extend an application process or make an employment offer … bauradio makita mit akku digitalWebAug 27, 2024 · Bio-Thera Solutions and Hikma Pharmaceuticals have entered into a commercialisation and license agreement to commercialise a monoclonal antibody used … tina krajisnik muzWebAug 27, 2024 · Bio-Thera Solutions, Ltd., a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel … bauragWebAug 31, 2024 · Last week, Bio-Thera Solutions and Hikma Pharmaceuticals announced they have entered into an exclusive commercialization and license agreement to … tina krajsek samarWebAug 31, 2024 · Last week, Bio-Thera Solutions and Hikma Pharmaceuticals announced they have entered into an exclusive commercialization and license agreement to commercialize the proposed ustekinumab biosimilar ... baurado baumanagement gmbh markkleebergWebAug 27, 2024 · Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody that is a proposed biosimilar referencing Stelara ® (ustekinumab), in the United States (US). BAT2206 is currently in a … tina kranidiotou